Table 1 MRI features and histology/immunohistochemistry data of the included NST invasive breast carcinomas (n = 398).
Variables | N (%) |
|---|---|
MRI features | |
Lesion type (n = 398) | |
Mass | 345 (86.7) |
Non-mass enhancement (NME) | 103 (25.9) |
Lesion presentation (n = 398) | |
Unifocal mass | 217 (54.5) |
Multifocal mass/NME | 181 (45.5) |
Mass—shape (n = 345) | |
Oval/round | 124 (35.9) |
Irregular | 221 (64.1) |
Mass—margins (n = 345) | |
Circumscribed | 22 (6.4) |
Irregular | 215 (62.3) |
Spiculated | 108 (31.3) |
Mass—internal enhancement (n = 345) | |
Homogeneous | 31 (9.0) |
Heterogeneous | 270 (78.3) |
Rim enhancement | 44 (12.8) |
Mass—kinetic curve—initial phase (n = 345) | |
Slow/medium | 50 (14.5) |
Fast | 295 (85.5) |
Mass—kinetic curve—delayed phase (n = 345) | |
Persistent (type I) | 84 (24.3) |
Plateau | 114 (33.0) |
Washout | 147 (42.6) |
NME—distribution (n = 103) | |
Focal | 27 (26.2) |
Linear | 16 (15.5) |
Segmental | 46 (44.7) |
Regional | 9 (8.7) |
Diffuse | 4 (3.9) |
Multiple regions | 1 (1.0) |
Histology/Immunohistochemistry | |
Tumour grade (n = 386) | |
I | 62 (16.1) |
II | 165 (42.7) |
III | 159 (41.2) |
Nuclear grade (n = 397) | |
1 | 18 (4.5) |
2 | 133 (33.5) |
3 | 246 (62.0) |
ER expression (n = 398) | |
Negative | 101 (25.4) |
Positive | 297 (74.6) |
PgR expression (n = 398) | |
Negative | 122 (30.7) |
Positive | 276 (69.3) |
HER2 expression (n = 398) | |
Negative | 324 (83.9) |
Positive | 64 (16.1) |
Ki-67 expression (n = 398) | |
< 15% | 63 (15.8) |
≥ 15% | 325 (84.2) |
Immunophenotype (n = 398) | |
Luminal A | 50 (12.6) |
Luminal B | 191 (48.0) |
Luminal ER-low-positive | 26 (6.5) |
HER2 | 64 (16.1) |
Triple-negative | 67 (16.8) |
